Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical...

Area of Science:

• Oncology
• Pharmacology
• Biomarker Research

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally with limited treatment options.
• Sunitinib, a tyrosine kinase inhibitor targeting soluble vascular endothelial growth factor receptor-2 (sVEGFR2), did not meet its primary endpoint in advanced HCC.
• Understanding the relationship between drug exposure, biomarker dynamics, and clinical outcomes is crucial for HCC treatment development.

Purpose of the Study:

• To develop a pharmacokinetic-pharmacodynamic (PK/PD) model linking sunitinib exposure to tumor growth inhibition (TGI) and time-to-tumor progression (TTP) via sVEGFR2 dynamics.
• To evaluate sVEGFR2 as a predictive biomarker for TTP in HCC patients treated with sunitinib.
• To quantitatively assess the role of angiogenesis biomarker dynamics in predicting TTP.

Main Methods:

• Utilized pharmacokinetic-pharmacodynamic modeling to integrate drug concentration, sVEGFR2 levels, and clinical endpoints (TGI, TTP).
• Modeled the inhibition of sVEGFR2 release by active drug concentrations (sunitinib and its metabolite).
• Validated the model against literature-reported placebo treatment outcomes.

Main Results:

• Active drug concentration was found to inhibit sVEGFR2 release, and this inhibition correlated with TGI.
• Daily sVEGFR2 exposure emerged as a potential reliable predictor for TTP in advanced HCC patients.
• The developed model successfully quantified the link between angiogenesis biomarker dynamics and TTP.

Conclusions:

• Pharmacokinetic-pharmacodynamic modeling provides a quantitative framework to understand sunitinib's effects in HCC.
• Inhibition of sVEGFR2 is associated with tumor growth inhibition, suggesting its role in HCC response.
• Daily sVEGFR2 levels may serve as a valuable predictive biomarker for treatment outcomes in HCC.